Uma Sinha

Chief Tech/Sci/R&D Officer at EIDOS THERAPEUTICS, INC.

Net worth: 54 900 $ as of 2026-05-30

69 year

58 connections

Health Technology

Consumer Services

Finance

Profile

Currently, Uma Sinha occupies the position of Chief Scientific Officer of BridgeBio Pharma, Inc. and Chief Scientific Officer for Eidos Therapeutics, Inc. (a subsidiary of BridgeBio Pharma, Inc.). Dr. Sinha previously held the position of Chief Scientific Officer of Global Blood Therapeutics, Inc., Principal at COR Therapeutics, Inc., Senior Director-Cardiovascular at Millennium Pharmaceuticals, Inc., Principal at Genencor International, Inc. and Vice President & Head-Biology at Portola Pharmaceuticals, Inc. She received a doctorate from the University of Georgia and an undergraduate degree from Presidency College.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
PROKIDNEY CORP. CLASS A 0.02%	2026-05-27	30,000 ( 0.02% )	54 900 $	2026-05-30

Uma Sinha active positions

Companies	Position	Start
EIDOS THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	2016-05-31
BRIDGEBIO PHARMA, INC.	Chief Tech/Sci/R&D Officer	2016-03-31
PROKIDNEY CORP.	Director/Board Member	2022-06-30

All active positions of Uma Sinha

Former positions of Uma Sinha

Companies	Position	End
GLOBAL BLOOD THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	2015-05-31
PORTOLA PHARMACEUTICALS, INC.	Corporate Officer/Principal	2012-11-30
COR Therapeutics, Inc. COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops biopharmaceutical products for acute cardiovascular diseases	Corporate Officer/Principal	2001-12-31
PROKIDNEY A	Director/Board Member	-
Genencor International, Inc. Genencor International, Inc. BiotechnologyHealth Technology Develops and manufactures enzyme product solutions	Corporate Officer/Principal	-

See the detail of Uma Sinha's experience

Training of Uma Sinha

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Uma Sinha's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	11
COR Therapeutics, Inc. COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops biopharmaceutical products for acute cardiovascular diseases	Health Technology
Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment	Health Technology
Genencor International, Inc. Genencor International, Inc. BiotechnologyHealth Technology Develops and manufactures enzyme product solutions	Health Technology
Portola Pharmaceuticals LLC Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapeutics	Health Technology
University of Georgia University of Georgia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Presidency College Presidency College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Global Blood Therapeutics, Inc. Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder	Health Technology
Eidos Therapeutics, Inc. Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company	Health Technology
BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients	Health Technology
Social Capital Suvretta Holdings Corp. III Social Capital Suvretta Holdings Corp. III Financial ConglomeratesFinance Operates as a blank check company	Finance
ProKidney Corp. ProKidney Corp. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company	Health Technology